

### Abstract

The invention relates to a bicyclic oligopeptide or ester thereof having the capability to inhibit the glucagon receptor, comprised of:

- (a) a first cyclic group, which comprises at least one cysteine group and is formed by an  
5       amide bonding of the N-terminal amino acid with the second carboxylate group of a  
      diacid amino acid, and
  - (b) a second cyclic group which is formed by an amide bonding of an amino acid with the  
       $\alpha$ -carboxylate group of said diacid amino acid, and by a disulfide bonding of the C-  
      terminal cysteine and a cysteine group within the first cyclic group (a);  
10    and
- to the use of such bicyclic oligopeptides for the preparation of a medicament for the  
treatment or prevention of diseases, in which glucagon receptors are involved.